SA PRO
Free Account
Royalty Pharma plcRPRXNASDAQ
LOADING
|||
OverviewNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 91% recommend buying.

Consensus Rating
Buy
11 analysts·Moderate coverage
91%
Rating Distribution
Strong Buy
00%
Buy
1091%
Hold
19%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 10% higher.

Bear Case
$42.00
+6%
Consensus
$43.50
+10%
Bull Case
$45.00
+14%
Price Range11 analysts
Low
Consensus
High
$42.00
$45.00
Current Target
Current Price
$39.55
Upside to Target
$3.95

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 11, 2025Leerink Partners
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business'
Target:$45.00
+17.7%from $38.22
Sep 30, 2025Goldman Sachs
Royalty Pharma initiated with a Buy at Goldman Sachs
Target:$42.00
+19.1%from $35.25
Jul 10, 2025Morgan Stanley
Royalty Pharma price target raised to $54 from $51 at Morgan Stanley
Target:$54.00
+49.4%from $36.14
Sep 4, 2024Goldman Sachs
Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX)
Target:$51.00
+74.9%from $29.16
Jul 11, 2024Morgan Stanley
Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
Target:$51.00
+98.2%from $25.73
Jun 7, 2024Goldman Sachs
Royalty Pharma (RPRX) PT Raised to $50 at Goldman Sachs
Target:$50.00
+84.6%from $27.09
Jun 3, 2024UBS
Royalty Pharma downgraded to Neutral from Buy at UBS
Target:$28.00
+2.4%from $27.35
Dec 6, 2022Morgan Stanley
Morgan Stanley Maintains Overweight on Royalty Pharma, Lowers Price Target to $51
Target:$51.00
+19.0%from $42.87
Jun 13, 2022UBS
Royalty Pharma initiated with a Buy at UBS
Target:$47.00
+22.2%from $38.46

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance